Searched for
MANKIND PHARMA REVENUE
Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Sudip Bandyopadhyay bets on pharma, metals and select cyclicals as geopolitical risks easeEasing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Mankind Pharma profit jumps 30% on chronic therapy demand in Q4Mankind Pharma announced a significant 30 percent profit increase for the fourth quarter. This growth was fueled by strong demand for chron...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...
- Rupee at 95, crude at $120+: Why India's markets are flying blind into a stormMarket expert Sudip Bandyopadhyay warns Indian markets face significant risks. High oil prices and a potential monsoon deficit are major co...
- Mankind Pharma shares jump 2% as Morgan Stanley initiates coverage with Overweight call. Check target, upsideMankind Pharma share price surged 2% after Morgan Stanley initiated coverage with an 'Overweight' rating and a Rs 2,500 target price, citin...
- Mankind Pharma shares in focus after Q3 net profit drops 16% YoY to Rs 385 croreMankind Pharma's shares are in focus following a 16.5% YoY decline in Q3 net profit to Rs 385 crore, despite strong revenue growth of 24%. ...
- Mankind Pharma net profit drops 16% to Rs 385 crore in Q3FY25Mankind Pharma's Q3 FY25 net profit declined 16% YoY to ₹385 crore despite a 24% revenue increase to ₹3,230 crore. Domestic revenues rose 1...
- Mankind Pharma Q3 Results: Profit falls 16% to Rs 384 croreMankind Pharma on Thursday said its consolidated net profit declined 16.5 per cent to Rs 384 crore in the third quarter ended December 31, ...
- Mankind Pharma shares gain over 6% as profit jumps nearly 30% in Q2Mankind Pharma's shares surged by 6% after reporting a 29% rise in Q2 profits, reaching ₹658.88 crore. The company attributed this growth t...
- Mankind Pharma Q2 Results: Net profit rises 29% to Rs 659 crore, revenue up 13%Mankind Pharma witnessed a 29% surge in consolidated net profit, reaching Rs 658.88 crore in the second quarter, ending September 2024. Thi...
- Market not much enthused by Mankind's BSV buyAfter initially cheering the deal, the stock market gave its thumbs-down to Mankind acquiring BSV at the premium valuations of eight times ...
- Macquarie initiates coverage on Mankind Pharma, sees 30% upsideMankind Pharma derives 98% of its revenue from the domestic pharma market. Within its domestic business, 90% of its revenue comes from pres...
- Mankind Pharma may offer investors a better entry point after its listingBusiness: Unlike its peers, Mankind Pharma started in rural India and is now expanding to urban India. The company earns 97% of its revenue...
- Mankind Pharma to open manufacturing plant in US, invest Rs 300 crore"We wish to become a multinational pharma company by tapping the foreign markets," Chairman and Founder RC Juneja said.
- Mankind Pharma launches diabetes drug 'Dynaglipt'Mankind Pharma has launched an anti-diabetic product 'Dynaglipt' targeting the middle class and rural diabetic patients.
Load More
